A Non-Randomised Open-Label Phase Ib Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Recurrent Oncogenic RAS Exon 2 Mutant Rectal Cancer

Trial Profile

A Non-Randomised Open-Label Phase Ib Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Recurrent Oncogenic RAS Exon 2 Mutant Rectal Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Apr 2017

At a glance

  • Drugs TG 02 (Primary) ; Pembrolizumab
  • Indications Colorectal cancer
  • Focus Adverse reactions; First in man
  • Sponsors Targovax
  • Most Recent Events

    • 20 Apr 2017 According to a Targovax ASA media release, the first patient has been enrolled in this trial.
    • 13 Oct 2016 Status changed from not yet recruiting to recruiting.
    • 02 Jun 2016 Status changed from planning to not yet recruiting, according to a Targovax media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top